CD133、CD90在肝癌组织中的表达及其临床意义

目的 检测肝癌干细胞标志物CD133和CD90在原发性肝癌组织中的表达情况,分析其临床病理学意义.方法 取93例原发性肝癌和10例正常肝组织,采用免疫组织化学(SP法)染色检测CD133和CD90表达.结果 93例肝癌组织中,71例(76.3%)CD133表达阳性,阳性细胞百分数为(6.4±3.3)%,64例(68.8%)CD90表达阳性,阳性细胞百分数为(4.3±3.9)%,10例正常肝组织中未见CD133和CD90阳性表达,差异有统计学意义(P<0.01);肝癌TNM分期Ⅲ～Ⅳ期患者CD133和CD90阳性细胞百分数(8.1±3.7)%,(5.7±4.2)%]显著高于Ⅰ～Ⅱ期(4.1±2.3)%,(2.3±1.9)%](P<0.01);Spearman相关分析显示,随病理组织学分级级别增高,CD133和CD90的表达增多(P<0.05);CD133与CD90在肝癌组织中的表达呈正相关(r=0.402,P<0.01).结论 肝癌组织中存在CD133和CD90阳性肝癌干细胞,其表达量与肝癌TNM分期和病理组织学分级呈正相关.

Expressions of CD133 and CD90 in hepatocellular carcinoma tissues and their clinical significances

Objective To investigate the expressions of hepatorna stem cell surface marker CD133 CD90 in tissues of hepatocellular carcinoma (HCC) and evaluate their related clinical significances. Method The expressions of CD133 CD90 were detected by immunohistochemical method in HCC tissues of 93 patients, and normal liver tissues of 10 cases. Results Among 93 cases with HCC, the positive expression of CD133 were found in 71 cases (76.3%), and CD90 positive expression in 64 cases (68.8%), and the percentage of positive cells were (6.4±3.3)% and (4.3±3.9)% respectively. No positive expression of CD133 and CD90 was found in normal liver tissues (P<0.01). CD133, CD90 expressions in the HCC tissues of TNM stage Ⅲ-Ⅳ (8.1±3.7)%,(5.7±4.2)%] were higher than those of TNM stage Ⅰ - Ⅱ (4.1±2.3)%,(2.3±1.9)%] (P<0.01). Spearman correlation analysis indicated that the expressions of CD133 and CD90 were up-regulated as the pathohistology grades increased (P<0.05). Positive correlation was observed between CD133 and CD90 expression (r=0.402, P<0.01). Conclusions CD133, CD90 positive cells exist in HCC tissues, their expressions positively relate to the TNM stage and the pathohistology grades for HCC patients.